missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human DPF2 (aa 234-272) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (97%), Rat (97%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-84309 (PA5-84309. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The protein encoded by this gene is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It likely serves a regulatory role in rapid hematopoietic cell growth and turnover. This gene is considered a candidate gene for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors.
Specifications
Specifications
| Accession Number | Q92785 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 5977 |
| Name | Human DPF2 (aa 234-272) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2210010M07Rik; apoptosis response zinc finger protein; BAF45D; BRG1-associated factor 45 D; D4, zinc and double PHD fingers family 2; double PHD fingers 2; Dpf2; neuro-d4/requiem; protein requiem; Req; requiem; requiem, apoptosis response zinc finger; UBID4; ubi-d4; Zinc finger protein ubi-d4 |
| Common Name | DPF2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction